Schering-Plough Coricidin repositioning targets hypertension concerns with decongestants.
This article was originally published in The Tan Sheet
Executive Summary
CORICIDIN COUGH/COLD LINE REPOSITIONING TARGETS HYPERTENSION CONCERNS by highlighting the fact three of the products do not contain decongestant ingredients such as pseudoephedrine/ephedrine, phenylephrine and phenylpropanolamine that may cause problems for those with high blood pressure or interfere with medication for the condition. Schering-Plough has repackaged its Coricidin Cold & Flu Tablets, Cold & Cough Tablets and NightTime Cold & Cough Liquid and renamed the line Coricidin HBP. The products are expected to reach stores by the end of January.
You may also be interested in...
Schering Coricidin HBP "Call to Action" Materials Going Out To Physicians
Schering-Plough HealthCare Products began sending "Providers' Care Package[s]" to physicians nationwide Sept. 14 in a campaign highlighting three of its cough, cold and flu products that do not contain a decongestant.
Schering Coricidin HBP "Call to Action" Materials Going Out To Physicians
Schering-Plough HealthCare Products began sending "Providers' Care Package[s]" to physicians nationwide Sept. 14 in a campaign highlighting three of its cough, cold and flu products that do not contain a decongestant.
Schering Coricidin HBP "Call to Action" Materials Going Out To Physicians
Schering-Plough HealthCare Products began sending "Providers' Care Package[s]" to physicians nationwide Sept. 14 in a campaign highlighting three of its cough, cold and flu products that do not contain a decongestant.